Airway hyperresponsiveness (AHR) is a central abnormality in asthma. IL-5 may modulate AHR in animal models of asthma, but the available data is inconsistent on the impact of targeting IL-5 pathway against AHR. The difference between targeting IL-5 or the IL-5 receptor, α subunit (IL-5Rα) in modulating AHR remains to be investigated in human airways. The aim of this study was to compare the role of the anti-IL-5Rα benralizumab and the anti-IL-5 mepolizumab against AHR and to assess whether these agents influence the levels of cAMP.
Calzetta, L., Ritondo, B.l., Matera, M.g., Facciolo, F., Rogliani, P. (2020). Targeting IL-5 pathway against airway hyperresponsiveness: a comparison between benralizumab and mepolizumab. BRITISH JOURNAL OF PHARMACOLOGY, 177(20), 4750-4765 [10.1111/bph.15240].
Targeting IL-5 pathway against airway hyperresponsiveness: a comparison between benralizumab and mepolizumab
Rogliani, Paola
2020-10-01
Abstract
Airway hyperresponsiveness (AHR) is a central abnormality in asthma. IL-5 may modulate AHR in animal models of asthma, but the available data is inconsistent on the impact of targeting IL-5 pathway against AHR. The difference between targeting IL-5 or the IL-5 receptor, α subunit (IL-5Rα) in modulating AHR remains to be investigated in human airways. The aim of this study was to compare the role of the anti-IL-5Rα benralizumab and the anti-IL-5 mepolizumab against AHR and to assess whether these agents influence the levels of cAMP.| File | Dimensione | Formato | |
|---|---|---|---|
|
lite bph.15240.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
3.17 MB
Formato
Adobe PDF
|
3.17 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
